Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Atara Biotherapeutics, Inc. Pioneering off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.	United States of America	ATRA
Atea Pharmaceuticals, Inc. A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.	United States of America	AVIR
Athira Pharma, Inc. Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.	United States of America	ATHA
ATOSSA THERAPEUTICS, INC. Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.	United States of America	ATOS
ATUM CO., LTD. Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.	South Korea	355690
aTYR PHARMA INC Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.	United States of America	ATYR
Aura Biosciences, Inc. Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.	United States of America	AURA
Aurinia Pharmaceuticals Inc. Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.	United States of America	AUPH
AURORA CANNABIS INC A global producer and seller of medical and recreational cannabis and derivative products.	United States of America	ACB
Autolus Therapeutics plc Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.	United States of America	AUTL